Cavion is committed to rapidly moving our technology into the clinic for the benefit of patients. We have conducted two oncology clinical trials studying the use of Cav3 blockers for the treatment of brain cancer, and we are actively engaged in research to determine next indications. We will launch a neurology clinical trial in essential tremor in 2017.
TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM ::: This Phase 1 trial was based at Yale University and run in partnership with Cavion. This was a dose-escalation study to assess the safety and determine the maximum tolerated dose (MTD) of mibefradil dihydrochloride, a partially selective T-type calcium channel blocker, combined with hypofractionated radiation therapy (RT) in subjects with recurrent glioblastoma multiforme (GBM). For more information, please visit the trial page at ClinicalTrials.gov.
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma ::: This Phase 1 study at six Adult Brain Tumor Consortium sites completed enrollment in 2014. Preliminary results were presented at the Annual Society of Clinical Oncology Annual Meeting in Chicago in June 2015. Those results can be viewed here. More information on the trial can be viewed at the trial page at ClinicalTrials.gov.
Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers ::: The objective of the study was to determine the safety and pharmacokinetics of a 7-day course of oral mibefradil given four times a day in healthy volunteers. This was a dose escalation study in which the total daily dose of mibefradil was increased with each cohort. More information can be found on the trial page at ClinicalTrials.gov.